Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-03-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's actual controllers. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company stock, the pledge terms, and assurances about the financial status and control implications. There are no financial statements, earnings data, or management discussion of results. The document is short (1920 characters) and focuses on a specific capital-related event (share pledge). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2023-03-17 Chinese
关于全资子公司为上市公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 瑞康医药集团股份有限公司 regarding its wholly-owned subsidiaries providing guarantees for the listed company. It details the guarantee amounts, approval procedures, financial data summary, and compliance with regulatory requirements. The document is a formal disclosure about a financing guarantee arrangement, not a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management discussion. It is a regulatory announcement about a specific corporate action (providing guarantees) and related financial exposure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-13 Chinese
关于全资子公司为上市公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a guarantee provided by a wholly-owned subsidiary for the listed company. It includes details about the guarantee amount, approval procedures, financial data summary, and compliance with regulatory requirements. The document is relatively short (2420 characters) and focuses on a specific corporate action related to financing guarantees rather than presenting comprehensive financial statements or detailed financial performance. It does not contain full financial reports, audit opinions, or earnings highlights. It is a regulatory announcement about a financing guarantee, which fits best under the category of Capital/Financing Update (CAP).
2023-02-22 Chinese
瑞康医药2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions from the 2023 first extraordinary general meeting (临时股东大会) of 瑞康医药集团股份有限公司. It details the meeting notice, attendance, voting results, and legal opinion on the meeting's validity. The document does not contain financial statements or detailed financial analysis but reports the official voting results of shareholder decisions. The length is short (1551 characters) and the content matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-02-01 Chinese
关于瑞康医药集团股份有限公司2023年第一次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 first extraordinary general meeting (EGM) of shareholders of Ruikang Pharmaceutical Group Co., Ltd. It details the legal verification of the convening, attendance, agenda, voting procedures, and results of the EGM. The document does not contain financial statements or financial performance data but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and legal compliance of a shareholder meeting.
2023-02-01 Chinese
关于2022年员工持股计划非交易过户完成暨回购股份处理完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a 2022 employee stock ownership plan involving non-trade transfer of shares and handling of repurchased shares. It details the stock source, stock scale, account opening, subscription, transfer, and repurchase handling. It references regulatory guidelines and includes specifics about the stock repurchase and employee participation. The document is relatively short (3322 characters) and is an announcement of the progress and completion of a specific employee stock plan, not a full financial report or audit. It does not contain financial statements or detailed financial analysis but rather updates on capital structure related to employee stock ownership and repurchased shares. This fits best under Capital/Financing Update (CAP) as it concerns share repurchase and employee stock plan implementation details.
2023-02-01 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.